Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the anti-viral effects of low-dose AZM treatment
in patients with asthma and COPD with an exacerbation history.
The investigators expect that long-term treatment with low dose AZM modulates the immune
response to viral infections, with an increased interferon release, in patients with asthma
and COPD with an exacerbation history. In addition, the investigators expect a decrease in
inflammatory cells and mediators, and changes in bacteria, measured in samples from the
lungs.
Half of the participants will receive azithromycin on top of their regular asthma/COPD
treatment, while the other half will receive placebo on top of their regular asthma/COPD
treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Bispebjerg Hospital
Collaborators:
Herlev and Gentofte Hospital Lund University University of Copenhagen